Homocysteine: Vascular Biochemistry and Metabolism

同型半胱氨酸：血管生物化学和代谢

• 批准号: 7822182
• 负责人: Donald Weldon Jacobsen
• 金额: $ 1.82万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2010-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7822182
• 关键词: Accounting; Adverse effects; Affect; Albumins; American; Antioxidants; Atherosclerosis; Biochemistry; Blood Circulation; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Cell physiology; Cells; Clinical Research; Cysteine; Diet; Disulfides; End stage renal failure; Endoplasmic Reticulum; Endothelial Cells; Equilibrium; Etiology; Folic Acid; Functional disorder; Genetic; Genotype; Growth Factor; Health Benefit; Homeostasis; Homo; Homocysteine; Homocystine; Human; Hyperhomocysteinemia; Impaired cognition; Incidence; Inflammatory; Intervention; Laboratories; Lead; Link; Macroglobulins; Mediating; Mediator of activation protein; Metabolism; Metallothionein; Molecular Target; Monocyte Chemoattractant Protein-1; Morbidity - disease rate; Myocardial Infarction; NF-kappa B; Neural Tube Defects; Nutrient; Osteoporosis; Pathology; Patients; Plasma; Play; Pregnancy Complications; Primary Prevention; Process; Proteins; Proteome; Proteomics; Public Health; Refractory; Research; Research Personnel; Risk Factors; Role; Signal Transduction; Smooth Muscle Myocytes; Source; Stroke; Sulfhydryl Compounds; System; Text; Therapeutic Intervention; Up-Regulation; Vascular Endothelium; Work; Zinc; atherogenesis; conventional therapy; cytokine; enantiomer; extracellular; high risk; improved; insight; loss of function; mortality; novel; programs; protein function; research study; response

DESCRIPTION (provided by applicant): Hyperhomocysteinemia is a modifiable, independent risk factor for cardiovascular disease, cognitive dysfunction, complications of pregnancy, and osteoporosis. Homocysteine-induced endothelial cell dysfunction may link this diverse group of pathologies. Our research has focused on: 1) the vascular biochemistry of homocysteine; 2) the mechanism of homocysteine transport in cultured human aortic endothelial cells; and, 3) the molecular targeting of protein cysteine residues by homocysteine. Thiol-disulfide exchange accounts for the forms of homocysteine in circulation. Cysteine transporters mediate homocysteine import in the vascular endothelium. Evidence is provided that links homocysteine targeting to vascular cell dysfunction. The long-term objectives are to understand the mechanism of homocysteine-accelerated atherogenesis and to develop improved interventional strategies that will lower plasma total homocysteine in high-risk subjects and in subjects who are refractory to conventional therapy (e.g., end-stage renal disease). Our central hypotheses are: 1) homocysteine is a mediator of early atherogenesis but becomes a marker in advanced atherosclerosis (we call this the "mediator ?>? marker hypothesis" of hyperhomocysteinemia); 2) monocyte chemoattractant protein 1 and other pro-inflammatory cytokines are induced by homocysteine in early atherogenesis by a mechanism involving the activation of NF-kB; 3) the fundamental mechanism underlying homocysteine causality is molecular targeting; and, 4) homocysteine-lowering by primary intervention will reduce mortality and morbidity associated with hyperhomocysteinemia. Our specific aims are: 1) to study the mechanism of protein homocysteinylation and functional consequences; 2) to study the transport and metabolism of homocysteine and its disulfide congeners in vascular cells; and, 3) to identify intracellular proteins (e.g., metallothionein) targeted by homocysteine and how loss of function of targeted proteins leads to vascular cell dysfunction. The program to fortify the American diet with folic acid, completed in January, 1998, has had a profound effect on reducing the incidence of hyperhomocysteinemia, neural tube defects and, possibly, mortality due to stroke and heart attack. Additional public health benefits are likely by gaining a better understanding of homocysteine transport, metabolism and the adverse effects of homocysteine on our circulatory system.

描述（由申请人提供）：高同型半胱氨酸血症是心血管疾病、认知功能障碍、妊娠并发症和骨质疏松症的可改变的独立危险因素。同型半胱氨酸诱导的内皮细胞功能障碍可能与这组不同的病理有关。主要研究方向为：1)同型半胱氨酸的血管生化；2)人主动脉内皮细胞同型半胱氨酸转运机制；3)同型半胱氨酸对蛋白质半胱氨酸残基的分子靶向。硫-二硫交换解释了同型半胱氨酸在循环中的形式。半胱氨酸转运体介导同型半胱氨酸在血管内皮中的输入。有证据表明，同型半胱氨酸靶向与血管细胞功能障碍有关。长期目标是了解同型半胱氨酸加速动脉粥样硬化的机制，并制定改进的介入策略，以降低高风险受试者和常规治疗难治性受试者（如终末期肾病）的血浆总同型半胱氨酸。我们的中心假设是：1)同型半胱氨酸是早期动脉粥样硬化的中介，但在晚期动脉粥样硬化中成为一个标志物（我们称之为“中介”）。标记假说（高同型半胱氨酸血症）；2)同型半胱氨酸在动脉粥样硬化早期诱导单核细胞趋化蛋白1和其他促炎细胞因子，其机制涉及NF-kB的激活；3)同型半胱氨酸致病的根本机制是分子靶向；4)通过初级干预降低同型半胱氨酸将降低高同型半胱氨酸血症相关的死亡率和发病率。我们的具体目标是：1)研究蛋白质同型半胱氨酸化的机制和功能后果；2)研究同型半胱氨酸及其二硫同系物在血管细胞中的转运和代谢；3)鉴定同型半胱氨酸靶向的细胞内蛋白（如金属硫蛋白），以及靶向蛋白的功能丧失如何导致血管细胞功能障碍。在美国人的饮食中添加叶酸的计划于1998年1月完成，对降低高同型半胱氨酸血症、神经管缺陷以及可能的中风和心脏病引起的死亡率产生了深远的影响。通过更好地了解同型半胱氨酸的运输、代谢以及同型半胱氨酸对我们循环系统的不利影响，可能会对公共卫生产生额外的好处。